A proposal for an updated staging system for LCHADD retinopathy.

LCHAD deficiency LCHADD chorioretinopathy staging

Journal

Ophthalmic genetics
ISSN: 1744-5094
Titre abrégé: Ophthalmic Genet
Pays: England
ID NLM: 9436057

Informations de publication

Date de publication:
30 Jan 2024
Historique:
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: aheadofprint

Résumé

To develop an updated staging system for long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency (LCHADD) chorioretinopathy based on contemporary multimodal imaging and electrophysiology. We evaluated forty cases of patients with genetically confirmed LCHADD or trifunctional protein deficiency (TFPD) enrolled in a prospective natural history study. Wide-field fundus photographs, fundus autofluorescence (FAF), optical coherence tomography (OCT), and full-field electroretinogram (ffERG) were reviewed and graded for severity. Two independent experts first graded fundus photos and electrophysiology to classify the stage of chorioretinopathy based upon an existing published system. With newer imaging modalities and improved electrophysiology, many patients did not fit cleanly into a single traditional staging group. Therefore, we developed a novel staging system that better delineated the progression of LCHADD retinopathy. We maintained the four previous delineated stages but created substages A and B in stages 2 to 3 to achieve better differentiation. Previous staging systems of LCHADD chorioretinopathy relied on only on the assessment of standard 30 to 45-degree fundus photographs, visual acuity, fluorescein angiography (FA), and ffERG. Advances in recordings of ffERG and multimodal imaging with wider fields of view, allow better assessment of retinal changes. Following these advanced assessments, seven patients did not fit neatly into the original classification system and were therefore recategorized under the new proposed system. The new proposed staging system improves the classification of LCHADD chorioretinopathy, with the potential to lead to a deeper understanding of the disease's progression and serve as a more reliable reference point for future therapeutic research.

Identifiants

pubmed: 38288966
doi: 10.1080/13816810.2024.2303682
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Auteurs

Nida Wongchaisuwat (N)

Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Melanie B Gillingham (MB)

Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.

Paul Yang (P)

Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.

Lesley Everett (L)

Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.

Ashley Gregor (A)

Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.

Cary O Harding (CO)

Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.

Jose Alain Sahel (JA)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Ken K Nischal (KK)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Hannah L Scanga (HL)

Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Danielle Black (D)

Division of Genetic and Genomic Medicine, University of Pittsburgh Medical Center Children's Hospital, Pittsburgh, Pennsylvania, USA.

Jerry Vockley (J)

Division of Genetic and Genomic Medicine, University of Pittsburgh Medical Center Children's Hospital, Pittsburgh, Pennsylvania, USA.

Georgianne Arnold (G)

Division of Genetic and Genomic Medicine, University of Pittsburgh Medical Center Children's Hospital, Pittsburgh, Pennsylvania, USA.

Mark E Pennesi (ME)

Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.

Classifications MeSH